GHK-Cu (Copper Peptide)

1.Overview

Simple explanation: GHK-Cu is a naturally occurring, very small protein fragment (three amino acids) bound to a copper ion, found in human blood, saliva, and wound fluid. It's best known as an ingredient in skin-care products, where controlled trials show it can improve measures like collagen density and wrinkle depth. It's also sold as an injectable research compound, though that use has essentially no dedicated human trial support of its own.

Scientific explanation: GHK-Cu is the copper(II) chelate of the tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys). Free GHK has a molecular weight of approximately 340.4 Da; the copper complex is approximately 403.9 g/mol (PubChem CID 71587328 for the complex; CID 73587 for the free peptide, per secondary chemical-reference sourcing — verify directly against PubChem before publication). GHK has a high natural affinity for Cu(II) and is proposed to play a role in normal cellular copper handling.

2.Discovery & Historical Development

• 1973 — Loren Pickart and Melvin Thaler reported that a low-molecular-weight fraction of young human plasma caused old human liver tissue explants to synthesize proteins in a pattern resembling younger tissue; the active factor was subsequently identified as the tripeptide glycyl-L-histidyl-L-lysine (Pickart & Thaler, 1973, per multiple secondary historical reviews — primary paper citation should be independently pulled before publication).
• 1977 — David Schlesinger (Harvard University Department of Chemistry) confirmed the growth-modulating peptide's identity as Gly-His-Lys (per secondary sourcing; primary citation not independently verified in this pass).
• Late 1980s — J.P. Borel and F. Maquart (Université de Reims Champagne-Ardenne, France) advanced GHK-Cu as a candidate wound-healing agent, reporting collagen stimulation in skin fibroblasts and dermal wound models in rats at picomolar-to-nanomolar concentrations, and proposed that the GHK sequence — present within collagen itself — is released from the extracellular matrix as an "emergency response" signal after tissue injury.
• 1983 — Linus Pauling and colleagues explored a related copper-binding tripeptide (Gly-Gly-His) combined with copper and ascorbic acid as an experimental cytotoxic strategy against Ehrlich ascites tumor cells in mice; Pickart's group later tested an analogous GHK-copper-ascorbate approach against sarcoma-180 tumors in mice (2014 paper) — see Section 14 for how this line of work fits into the broader cancer evidence-quality picture.
• 1990s–2000s — Attempted pharmaceutical drug development under the names "Iamin" (topical wound-healing candidate) and FDA substance registration as "Prezatide Copper" (UNII 6BJQ43T1I9); this drug-development pathway did not result in FDA marketing approval, and GHK-Cu instead became widely established as a cosmetic ingredient (INCI name "Copper Tripeptide-1").
• 2009 — Watson et al. published a double-blind, randomized controlled trial in the British Journal of Dermatology demonstrating measurable improvements in photoaged skin from a GHK-Cu-containing cosmetic product — widely cited as the strongest single piece of human RCT evidence for this compound (Section 7).
• 2010s–present — Large-scale gene-expression (transcriptomic) work, closely associated with Pickart and colleagues (including analyses drawing on the Broad Institute's Connectivity Map), reframed GHK from a single-pathway wound-healing signal to what these authors describe as a broad modulator of human gene expression (Pickart & Margolina, 2018, and related papers).
• 2023 (EurekAlert press release) — A California biotechnology company (Yuvan Research Inc.) reported results from a small (n=21), industry-sponsored, IRB-approved human trial of a proprietary topical GHK-Cu gel formulation showing an average 28% increase in dermal collagen density by ultrasound after 3 months; this is a company press release, not an independently published peer-reviewed paper, and should be treated accordingly pending journal publication.

3.Molecular Biology — Route-of-Administration Split

Unlike BPC-157 or TB-500, GHK-Cu does not have a single "identity ambiguity" problem — the molecule itself is well-defined and consistently characterized across sources (Gly-His-Lys + Cu²⁺). The critical distinction for this compound is route of administration and regulatory category, not molecular identity.

This monograph does not treat topical and injectable evidence as interchangeable anywhere below. Any claim about GHK-Cu's effects should specify which route of administration the underlying evidence used.

4.Mechanism of Action

• Copper delivery/chelation chemistry (core mechanism): GHK's defining biochemical property is high-affinity Cu(II) binding; the resulting complex is proposed to function in normal cellular copper trafficking and to deliver copper as a cofactor to copper-dependent enzymes, including lysyl oxidase (essential for collagen/elastin cross-linking) — a mechanism cited across multiple secondary and vendor sources, consistent with the compound's well-established effect on collagen synthesis.
• Extracellular matrix signaling: Borel and Maquart's foundational work proposed that GHK sequence fragments are released from collagen/the extracellular matrix at sites of injury, acting as a "tissue repair is needed here" signal — a mechanism distinct from, but complementary to, the copper-delivery function.
• Anti-inflammatory/antioxidant effects: Multiple papers (reviewed in Pickart, 2012, Oxid Med Cell Longev) describe GHK-Cu increasing antioxidant enzyme activity and reducing inflammatory markers in various tissue models.
• Broad gene-expression modulation: Transcriptomic analyses associated with Pickart and colleagues report that GHK modulates a very large number of human genes — cited variously as "more than 4,000 genes" or "approximately 31% of analyzed genes" via Connectivity Map-based analysis (Campbell et al., cited secondarily; Pickart & Margolina, 2018) — with reported effects concentrated in tissue-repair, antioxidant, anti-inflammatory, and (per some papers) DNA-repair gene categories. This is one of the broadest gene-expression-modulation claims made for any peptide reviewed in this library, and the underlying Connectivity Map methodology and its interpretation should be independently understood (not just cited) before being restated as an established mechanism — bioinformatic "connectivity" associations are not the same evidentiary tier as a validated, mechanism-specific pathway study.
• No single dedicated receptor: unlike some peptides, GHK-Cu's effects are not attributed in the literature to one specific cell-surface receptor; the copper-chelation chemistry and broad transcriptional effects are presented as the operative mechanism(s) instead.

5.Why Researchers Study It

GHK-Cu draws research interest from an unusually wide set of fields — dermatology/cosmetic science (by far the most human-trial-supported area), wound healing, hair biology, hepatology (liver regeneration), pulmonology (lung tissue remodeling, including COPD-related gene-expression work), bone biology, and — more speculatively — oncology and neurodegeneration/cognitive health (Pickart, 2012).

Limitations/gaps specific to this compound:

• Much of the gene-expression and mechanistic literature is concentrated among a relatively small set of authors closely associated with Pickart's research program; independent replication of the specific transcriptomic claims (as opposed to the more basic collagen-stimulation findings, which are independently replicated) is comparatively limited.
• The injectable/systemic route — the form most actively marketed in the research-compound and longevity-clinic space — has essentially no dedicated human trial evidence, in contrast to the topical/cosmetic route.
• The cancer-related literature specifically requires careful handling (Section 14).

6.Pharmacokinetics

• Topical absorption: Human RCTs of topical GHK-Cu formulations report measurable skin-level effects (collagen density, wrinkle parameters) after 8–12 weeks of daily/twice-daily application; systemic absorption from topical use is understood to be minimal, consistent with its regulatory treatment as a cosmetic rather than a systemic drug.
• Endogenous plasma levels: GHK is reported present in human plasma at approximately 200 ng/mL (some sources report ~200 µg/L, i.e., the same order of magnitude expressed differently — reconcile units before publication) in individuals aged 20–25, declining to approximately 80 ng/mL by age 60 — a roughly 60% age-related decline cited across multiple secondary reviews of Pickart's original quantitative work; the underlying original dataset is described as a small set of analyses rather than a large independent population survey, per at least one secondary source, and should be weighted accordingly.
• Distribution: GHK is also detected in saliva, urine, and wound fluid.
• Metabolism/elimination: No detailed validated human PK study (systemic half-life, clearance, metabolism pathway) for injectable GHK-Cu was identified in this review; this is an explicit gap.
• Injectable bioavailability: No published human PK study of subcutaneous GHK-Cu injection was identified.

7.Human Clinical Evidence

All entries above used topical/cosmetic formulations. No human trial of injectable GHK-Cu was identified.

Bottom line: Topical GHK-Cu has a genuine, multi-decade, multi-study human RCT record for cosmetic skin endpoints, including at least one trial in a recognized dermatology journal (Watson et al., 2009). Injectable/systemic GHK-Cu has no comparable human trial record.

8.Animal Research

• Wound healing (rat): Foundational work by Borel, Maquart, and colleagues (late 1980s) demonstrated GHK-Cu-stimulated collagen, total protein, glycosaminoglycan, and DNA synthesis in rat dermal wounds at picomolar-to-nanomolar concentrations.
• Combined laser/peptide wound therapy (rabbit): GHK (alone or combined with high-dose helium-neon laser) improved wound contraction and granulation tissue formation in rabbit experimental wounds (cited via PMC6073405 review).
• Cancer models (mouse): Pauling and colleagues (1983) reported inhibition of Ehrlich ascites tumor growth in mice using a related copper-binding tripeptide/ascorbate system; Pickart's group (2014 paper) reported suppression of sarcoma-180 tumor growth in mice using a GHK-copper-ascorbate approach. These are specific, narrow experimental tumor models and should not be generalized to a broad "anti-cancer" claim without the qualifications discussed in Section 14.
• Liver regeneration: Original 1973 findings involved ex vivo human liver tissue explants (not a live-animal study); subsequent animal liver-protection work is referenced in review literature (Pickart, 2012) but was not independently re-verified against primary papers in this pass.
• Lung tissue remodeling: Secondary review sourcing describes GHK shifting gene expression in COPD-affected lung tissue "from destruction to healthy remodeling" — this is a gene-expression/transcriptomic claim, not a demonstrated clinical or even whole-animal physiological outcome, and should be read at that evidentiary tier.
• Hair follicle research: GHK-Cu is referenced across multiple secondary/vendor sources as supporting hair follicle health; a specific, independently verifiable primary animal or human hair-growth trial citation was not confidently isolated in this research pass and should be sourced directly before making a specific hair-growth claim in a final published version.

What has/hasn't translated: the collagen-stimulation/wound-healing mechanism is well replicated from foundational 1980s rat work through to modern human topical RCTs — a genuinely coherent evidence chain. The cancer-model and lung-remodeling findings are comparatively narrow, concentrated among fewer independent sources, and should be presented with more caution (Section 14).

9.In Vitro Research

• Fibroblast collagen/elastin/glycosaminoglycan stimulation: the core, most independently replicated in vitro finding, dating to Borel/Maquart-era work and confirmed across numerous subsequent papers.
• Gene-expression/transcriptomic analyses: Campbell and colleagues' Connectivity Map-based analysis (cited via Pickart & Margolina, 2018, and secondary review sourcing) reports GHK modulating expression of a very large gene set, including genes associated with DNA repair, apoptosis, cancer suppression, and cancer progression pathways (per the OBM Genetics paper's Tables 2–4, examining MCF7 breast cancer and PC3 prostate cancer cell lines specifically).
• Decorin upregulation: GHK-Cu is reported to increase decorin expression in dermal fibroblast cultures and rat wound tissue; decorin has independently described anti-tumorigenic properties in the broader cancer biology literature (down-regulating tyrosine kinases, suppressing proliferation/migration/angiogenesis) — this is presented in GHK-Cu-specific papers as a mechanistic link supporting anti-cancer potential (Section 14).
• DNA repair gene modulation: at least one secondary source describes GHK affecting "47 DNA repair genes" specifically; this figure was not independently traced to a primary paper in this research pass and should be verified before restating with that specificity.

10.Published Research Protocols

Human — Watson et al., 2009 (PMID 19438432)

• Species: Human; Design: double-blind, randomized, controlled
• Route: Topical cosmetic application
• Stated rationale: evaluate whether a cosmetic anti-aging product containing GHK-Cu could measurably improve photoaged skin parameters
• (Exact concentration, application frequency, and duration should be pulled from the primary paper before publication — not restated here from secondary summary alone.)

Human — nano-lipid-carrier RCT vs. Matrixyl® 3000 (cited via PMC6073405 review)

• Species: Human (female volunteers)
• Route: Topical, nano-lipid encapsulated formulation
• Frequency/duration: twice daily, 8 weeks
• Stated rationale: compare GHK-Cu's anti-wrinkle efficacy directly against an established commercial cosmetic peptide (Matrixyl® 3000) and vehicle control

Animal — Borel, Maquart et al. (foundational wound-healing work, late 1980s)

• Species: Rat
• Route: Local/dermal wound application
• Stated rationale: establish whether GHK-Cu at picomolar-to-nanomolar concentrations could stimulate collagen and extracellular matrix component synthesis in a controlled wound model
• (Exact dose/concentration/frequency should be pulled from the primary paper(s) before publication.)

Animal — Pickart et al., 2014, sarcoma-180 tumor model

• Species: Mouse
• Design: GHK-copper-ascorbate system tested against sarcoma-180 tumor growth
• Stated rationale: test a Pauling-inspired copper-ascorbate oxidative mechanism against tumor growth, following Pauling's 1983 work with a related copper-binding peptide
• (Exact dose/route/frequency should be pulled from the primary 2014 paper before publication — not restated here from secondary review summary alone.)

11.Formulation and Stability in Research Literature

• Physical/chemical form: GHK-Cu is a small, water-soluble, copper-coordinated tripeptide; its blue-green color derives from the coordinated Cu(II) ion and is a normal chemical property, not an irritation or degradation indicator (per multiple secondary vendor/consumer-facing sources — a genuinely useful, low-risk consumer-safety clarification worth retaining).
• Cosmetic formulation: widely incorporated into serums and creams at low percentage concentrations (cosmetic formulations reportedly up to ~0.002%, per secondary sourcing — verify against a formulation-chemistry primary source before publication).
• Copper-complex stability: at least one secondary industry-facing source describes copper-complex "stability across lots" and "what exactly is the active species in vivo" as open pharmaceutical chemistry/CMC (chemistry, manufacturing, controls) questions specifically relevant to injectable drug development — this is a genuine, non-trivial formulation science question distinct from the simpler topical-cosmetic use case, and should be treated as an open question rather than assumed to be resolved.
• What is not established: no validated, peer-reviewed, stability-indicating assay data specific to an injectable GHK-Cu drug product was identified in this review.

12.Toxicology & Safety

• Topical/cosmetic use: widely reported across decades of cosmetic use as generally well tolerated, with occasional mild application-site itching noted in some secondary/consumer sources; a dedicated, independent, peer-reviewed long-term topical safety/toxicology study was not specifically isolated in this pass beyond the RCTs already cited in Section 7, which reported good tolerability as a secondary endpoint.
• Injectable use: secondary/clinic-facing sources describe injection-site redness, mild swelling, bruising (typically resolving in 24–72 hours), and temporary skin darkening at the injection site attributed to local copper deposition (described as expected and reversible, not necessarily indicative of toxicity, per these sources — this characterization should be verified against an independent toxicology source before being restated as established fact).
• Copper-load/systemic considerations: because GHK-Cu delivers a copper ion, systemic/injectable use raises a theoretical concern around cumulative copper exposure with high or prolonged use, flagged by multiple secondary sources as a reason injectable use should be clinically supervised; individuals with Wilson's disease (a genetic disorder of copper accumulation) or known copper sensitivity/allergy are specifically flagged in secondary clinical-facing sources as needing physician guidance before use — this is a sensible precaution given the compound's mechanism, though a dedicated peer-reviewed copper-toxicology study specific to GHK-Cu injection was not independently located in this pass.
• FDA compounding-list history — reported inconsistently, requires verification: secondary sources reviewed for this monograph give materially different accounts of GHK-Cu's FDA Category 1/Category 2 bulk-substance history and current PCAC review timeline (one source describes removal from Category 2 in April 2026 with a PCAC review "before the end of February 2027"; GHK-Cu was notably not among the seven substances confirmed on the July 23–24, 2026 PCAC meeting agenda that included BPC-157, KPV, TB-500, MOTS-c, emideltide, Semax, and Epitalon — meaning GHK-Cu appears to be on a separate regulatory timeline from those compounds). This entire regulatory history should be independently verified directly against FDA.gov before any final publication; do not carry forward the specific dates in this draft as confirmed fact.
• WADA status: no listing of GHK-Cu on the WADA Prohibited List was identified in this research pass (unlike BPC-157 and TB-500); this should be confirmed against the current-year Prohibited List before stating it as an established negative (i.e., before affirmatively stating "not prohibited").

13.Regulatory Status

• Topical/cosmetic GHK-Cu: regulated as a cosmetic ingredient (INCI: Copper Tripeptide-1) in the US and most jurisdictions; cosmetic ingredients generally do not require FDA premarket approval, and GHK-Cu's cosmetic use is long-standing and widespread.
• Injectable GHK-Cu: not FDA-approved as a drug for any indication. An earlier pharmaceutical development pathway under the names "Iamin" and "Prezatide Copper" (UNII 6BJQ43T1I9) did not result in marketing approval. Current compounding-list (503A) status is reported inconsistently across secondary sources reviewed for this monograph and requires direct FDA.gov verification before publication (see Section 12).
• International: EU, Japanese (PMDA), and Australian (TGA) frameworks reportedly draw a similar line between permitted cosmetic use and restricted/unapproved therapeutic use, per secondary industry-facing sourcing — primary regulatory citations for each jurisdiction should be pulled before making jurisdiction-specific claims in a final published version.

14.Evidence Quality & Ongoing Scientific Debate

This section requires careful, undiluted presentation and should not be shortened for space.

The cancer question — two bodies of literature that point in different directions:

• GHK-Cu-specific research (concentrated substantially in Pickart and closely associated colleagues' publications) reports anti-cancer-relevant gene-expression effects — including upregulation of decorin (an independently described anti-tumorigenic extracellular matrix protein), favorable shifts in apoptosis/cancer-suppression gene panels in MCF7 and PC3 cell lines, and tumor-growth suppression in two narrow mouse models (Ehrlich ascites tumor cells using a related peptide, and sarcoma-180 using GHK-copper-ascorbate).
• Separately, a broader, independently replicated copper biology literature — not specific to GHK-Cu — associates increased bioavailable copper with stimulation of tumor angiogenesis (via VEGF, HIF-1α, and copper-dependent enzymes including lysyl oxidase and SOD1), and describes copper chelation/depletion (e.g., tetrathiomolybdate, penicillamine) as an active anti-angiogenic cancer-therapy strategy in oncology research.
• These two literatures have not been reconciled in this research pass. It is possible that GHK-Cu's specific chelated form, its very low effective concentrations, and its particular downstream gene-expression profile behave differently from the copper-loading mechanisms studied in the independent tumor-angiogenesis literature — but this monograph does not have a citation that directly tests and resolves that distinction. Presenting GHK-Cu as unambiguously "anti-cancer" would overstate a narrow, single-lab-concentrated evidence base; presenting it as straightforwardly dangerous would ignore genuine, if preliminary, GHK-Cu-specific data. The responsible position is to present both bodies of evidence and flag the unresolved tension explicitly — which is why several secondary consumer-facing sources reviewed for this monograph recommend that individuals with active or suspected cancer avoid GHK-Cu and consult a physician, a reasonable precautionary stance given the genuine uncertainty.

Gene-expression breadth as a double-edged evidentiary feature: a tripeptide reported to modulate thousands of genes, or ~31% of an analyzed panel, is either evidence of a remarkably fundamental biological signaling role, or a sign that Connectivity-Map-style bioinformatic association methods are picking up broad, non-specific correlations that require more targeted follow-up mechanistic study to interpret meaningfully. This monograph does not adjudicate between those two readings and presents the gene-expression breadth claim as reported, with this caveat attached.

Authorship concentration: a substantial share of the most expansive mechanistic and gene-expression claims about GHK-Cu trace back to Loren Pickart and a relatively small set of closely associated co-authors and affiliated companies (e.g., Skin Biology, Yuvan Research Inc.), which is a relevant consideration when weighing independence of replication — similar in structure to the single-research-group concentration noted for BPC-157, though the foundational collagen-stimulation and topical-RCT evidence for GHK-Cu is more independently replicated than BPC-157's core evidence base.

Injectable-use evidence gap: despite an active commercial/clinical market for injectable GHK-Cu, no human clinical trial of that specific route was identified — a significant and specific evidence gap distinct from the reasonably well-supported topical/cosmetic use case.

15.Frequently Asked Questions

16.Comparison With Similar Compounds

17.Fun Science & Historical Facts

Did you know? GHK-Cu's discovery started with a strikingly simple observation: mixing young human blood plasma with old liver tissue in a lab dish made the old tissue start behaving like young tissue again — a finding that eventually narrowed down to a single three-amino-acid molecule.

The color is the chemistry: GHK-Cu solutions and creams have a natural blue-green tint, the signature color of coordinated copper(II) — the same family of chemistry responsible for the green patina on aged copper statues, just at a vastly smaller and biologically active scale.

A tripeptide with an outsized transcriptional footprint: GHK is one of the few small peptides in this library reported to influence gene expression on a genome-wide scale in bioinformatic analyses — a genuinely unusual claim for a three-amino-acid molecule, and one of the more actively debated mechanistic questions covered in this monograph (Section 14).

18.Complete References

1. 1.Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243(124):85-87. (Primary citation reconstructed from secondary historical review sourcing — independently verify exact citation before publication.){{VERIFY}}
2. 2.Pickart L. The human tripeptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-988. (Representative review citation — verify.)
3. 3.Pickart L. The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging: Implications for Cognitive Health. Oxid Med Cell Longev. 2012;2012:324832.
4. 4.Gruchlik A, et al. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. (Journal/year to be independently confirmed — cited via PMC6073405.){{VERIFY}}
5. 5.Watson REB, Ogden S, Cotterell LF, et al. A cosmetic 'anti-ageing' product improves photoaged skin: a double-blind, randomized controlled trial. Br J Dermatol. 2009;161(2):419-426.PMID: 19438432
6. 6.Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters. J Aging Sci. 2016;4(3):166.
7. 7.Pickart L, et al. Modulation of Gene Expression in Human Breast Cancer MCF7 and Prostate Cancer PC3 Cells by the Human Copper-Binding Peptide GHK-Cu. OBM Genetics. (Year and volume to be confirmed against primary journal record.){{VERIFY}}
8. 8.Pauling L, et al. (1983 mouse Ehrlich ascites tumor study using a related copper-binding peptide) — primary citation to be independently confirmed before publication.{{VERIFY}}
9. 9.Pickart L, et al. (2014 mouse sarcoma-180 tumor study using GHK-copper-ascorbate) — primary citation to be independently confirmed before publication.{{VERIFY}}
10. 10.Badet J, et al. Proc Natl Acad Sci U S A. 1989;86:8427-8431. (Independent copper/angiogenesis literature, cited for the counter-perspective in Section 14.)
11. 11.Alvarez HM, et al. Science. 2010;327(5963):331-334. (Copper chelation as anti-angiogenic cancer strategy — independent copper literature, not GHK-Cu-specific.)
12. 12.Rapid Copper Acquisition by Developing Murine Mesothelioma: Decreasing Bioavailable Copper Slows Tumor Growth... (independent copper/cancer literature, cited via PMC3754934, for the counter-perspective in Section 14).
13. 13.U.S. Food and Drug Administration. Substance registration: Prezatide Copper, UNII 6BJQ43T1I9. (Verify directly against FDA/NLM substance registration records before publication.){{VERIFY}}
14. 14.EurekAlert!/Yuvan Research Inc. Epigenetic mechanisms activated by GHK-Cu increase skin collagen density in clinical trial (press release). 2023. (Company press release — not independently peer-reviewed as of this pass; upgrade to primary journal citation if/when published.)
15. 15.World Anti-Doping Agency. Prohibited List (current year) — GHK-Cu listing status not confirmed in this pass; verify directly.{{VERIFY}}

19.Revision History